|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 September 2002, Vol. 100, No. 6, pp. 2195-2202
NEOPLASIA
Role for macrophage inflammatory protein (MIP)-1 and MIP-1
in the development of osteolytic lesions in multiple myeloma
Masahiro Abe,
Kenji Hiura,
Javier Wilde,
Keiji Moriyama,
Toshihiro Hashimoto,
Shuji Ozaki,
Shingo Wakatsuki,
Masaaki Kosaka,
Shinsuke Kido,
Daisuke Inoue, and
Toshio Matsumoto
From the First Department of Internal Medicine, School
of Medicine, Department of Orthodontics, School of Dentistry, and First
Department of Pathology, School of Medicine, University of Tokushima,
and Tokushima Prefectural Hospital Kaifu, Tokushima, Japan.
Multiple myeloma (MM) cells cause devastating bone destruction by
activating osteoclasts in the bone marrow milieu. However, the
mechanism of enhanced bone resorption in patients with myeloma is
poorly understood. In the present study, we investigated a role of C-C
chemokines, macrophage inflammatory protein (MIP)-1 and
MIP-1 , in MM cell-induced osteolysis. These chemokines were produced and secreted by a majority of MM cell lines as well as primary
MM cells from patients. Secretion of MIP-1 and MIP-1 correlated
well with the ability of myeloma cells to enhance osteoclastic bone
resorption both in vitro and in vivo as well as in MM patients. In
osteoclastogenic cultures of rabbit bone cells, cocultures with myeloma
cells as well as addition of myeloma cell-conditioned media enhanced
both formation of osteoclastlike cells and resorption pits to an extent
comparable to the effect of recombinant MIP-1 and MIP-1.
Importantly, these effects were mostly reversed by neutralizing
antibodies against MIP-1 and MIP-1, or their cognate receptor,
CCR5, suggesting critical roles of these chemokines. We also
demonstrated that stromal cells express CCR5 and that recombinant
MIP-1 and MIP-1 induce expression of receptor activator of
nuclear factor- B (RANK) ligand by stromal cells, thereby stimulating osteoclast differentiation of preosteoclastic cells. These results suggest that MIP-1 and MIP-1 may be major osteoclast-activating factors produced by MM cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
O. Sezer
Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
Oncologist,
March 1, 2009;
14(3):
276 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lorenzo, M. Horowitz, and Y. Choi
Osteoimmunology: Interactions of the Bone and Immune System
Endocr. Rev.,
June 1, 2008;
29(4):
403 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Kominsky, S. M. Abdelmagid, M. Doucet, K. Brady, and K. L. Weber
Macrophage Inflammatory Protein-1{delta}: A Novel Osteoclast Stimulating Factor Secreted by Renal Cell Carcinoma Bone Metastasis
Cancer Res.,
March 1, 2008;
68(5):
1261 - 1266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
New potential targets for treating myeloma bone disease.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6270s - 6273s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Weinstock-Guttman, J. Hong, R. Santos, M. Tamano-Blanco, D. Badgett, K. Patrick, M. Baier, J. Feichter, E. Gallagher, N. Garg, et al.
Interferon-{beta} modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients
Multiple Sclerosis,
September 1, 2006;
12(5):
541 - 550.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Matsumoto and M. Abe
Myeloma-Bone Interaction: A Vicious Cycle
IBMS BoneKEy,
March 1, 2006;
3(3):
8 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Oshima, M. Abe, J. Asano, T. Hara, K. Kitazoe, E. Sekimoto, Y. Tanaka, H. Shibata, T. Hashimoto, S. Ozaki, et al.
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
Blood,
November 1, 2005;
106(9):
3160 - 3165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Shibata, M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Sano, K.-i. Kitazoe, T. Hashimoto, S. Ozaki, S. Wakatsuki, et al.
Malignant B-Lymphoid Cells with Bone Lesions Express Receptor Activator of Nuclear Factor-{kappa}B Ligand and Vascular Endothelial Growth Factor to Enhance Osteoclastogenesis
Clin. Cancer Res.,
September 1, 2005;
11(17):
6109 - 6115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. L. Coelho, G. M. de Freitas Almeida, F. J. D. Mennechet, A. Blangy, and G. Uze
Interferon-{alpha} and -{beta} differentially regulate osteoclastogenesis: Role of differential induction of chemokine CXCL11 expression
PNAS,
August 16, 2005;
102(33):
11917 - 11922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Ehrlich, H. Y. Chung, I. Ghobrial, S. J. Choi, F. Morandi, S. Colla, V. Rizzoli, G. D. Roodman, and N. Giuliani
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
Blood,
August 15, 2005;
106(4):
1407 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos and M.-A. Dimopoulos
Myeloma bone disease: pathophysiology and management
Ann. Onc.,
August 1, 2005;
16(8):
1223 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Oyajobi, C. M. Shipman, and G. R. Mundy
Recent Insights into Myeloma Bone Disease
IBMS BoneKEy,
May 1, 2005;
2(5):
17 - 25.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsumoto and M. Abe
The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions
IBMS BoneKEy,
February 1, 2005;
2(2):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kyle and S. V. Rajkumar
Multiple Myeloma
N. Engl. J. Med.,
October 28, 2004;
351(18):
1860 - 1873.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al.
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
Blood,
October 15, 2004;
104(8):
2484 - 2491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer
RANK ligand and osteoprotegerin in myeloma bone disease
Blood,
March 15, 2003;
101(6):
2094 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology,
January 1, 2003;
2003(1):
248 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
